Premature ovarian insufficiency: Genetic causes and treatment options. A literature review

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Premature ovarian insufficiency is a syndrome characterized by hypergonadotropic ovarian insufficiency and the reduction of ovarian function before age 40. This leads to reproductive failures, metabolic changes, and a decrease in quality of life. Currently, occult and initial forms of premature ovarian insufficiency, which have their own diagnostic features and management tactics, can be figured out. The frequency of this syndrome is between 1.1 and 3.7% and the tendency for incidence to increase can be seen. This article is a literature review of the data available in the PubMed database (2005–2020), with international clinical guidelines taken into consideration. The genetic causes of premature ovarian insufficiency, clinical signs of this pathology and treatments options for such patients are included into the review. In addition, some features of assisted reproductive technology within this group are described.

About the authors

Valentina M. Denisova

NGC Next Generation Clinic

Author for correspondence.
Email: valyik@mail.ru
ORCID iD: 0000-0001-6469-9111
SPIN-code: 7291-3857
Scopus Author ID: 57218170473

MD, Cand. Sci. (Med.)

Russian Federation, Saint-Petersburg

Maria I. Yarmolinskaya

The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott; North-Western State Medical University named after I.I. Mechnikov

Email: m.yarmolinskaya@gmail.com
ORCID iD: 0000-0002-6551-4147
SPIN-code: 3686-3605
Scopus Author ID: 7801562649
ResearcherId: P-2183-2014

MD, Dr. Sci. (Med.), Professor, Professor of the Russian Academy of Sciences

Russian Federation, Saint Petersburg

Karina A. Zakurayeva

The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Email: kareen07kbr@gmail.com
ORCID iD: 0000-0002-8128-306X
SPIN-code: 5215-7869

Resident Physician

Russian Federation, Saint Petersburg

References

  1. European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber L, Davies M, Anderson R, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926–937. doi: 10.1093/humrep/dew027
  2. Ossewaarde ME, Bots ML, Verbeek AL, et al. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology. 2005;16(4):556–562. doi: 10.1097/01.ede.0000165392.35273.d4
  3. Panay N, Anderson RA, Nappi RE, et al. Premature ovarian insufficiency: An International Menopause Society White Paper. Climacteric. 2020;23(5):426–446. doi: 10.1080/13697137.2020.1804547
  4. Torrealday S, Kodaman P, Pal L. Premature Ovarian Insufficiency — an update on recent advances in understanding and management. F1000Res. 2017;6:2069. doi: 10.12688/f1000research.11948.1
  5. Tucker EJ, Grover SR, Bachelot A, et al. premature ovarian insufficiency: new perspectives on genetic cause and phenotypic spectrum. Endocr Rev. 2016;37(6):609–635. doi: 10.1210/er.2016-1047.
  6. Voican A, Bachelot A, Bouligand J, et al. NR5A1 (SF-1) mutations are not a major cause of primary ovarian insufficiency. J Clin Endocrinol Metab. 2013;98(5):E1017–E1021. doi: 10.1210/jc.2012-4111
  7. Janse F, de With LM, Duran KJ, et al. Limited contribution of NR5A1 (SF-1) mutations in women with primary ovarian insufficiency (POI). Fertil Steril. 2012;97(1):141–6.e2. doi: 10.1016/j.fertnstert.2011.10.032
  8. Lourenço D, Brauner R, Lin L, et al. Mutations in NR5A1 associated with ovarian insufficiency. N Engl J Med. 2009;360(12):1200–1210. doi: 10.1056/NEJMoa0806228
  9. Jaillard S, Sreenivasan R, Beaumont M, et al. Analysis of NR5A1 in 142 patients with premature ovarian insufficiency, diminished ovarian reserve, or unexplained infertility. Maturitas. 2020;131:78–86. doi: 10.1016/j.maturitas.2019.10.011
  10. Crisponi L, Deiana M, Loi A, et al. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet. 2001;27(2):159–166. doi: 10.1038/84781
  11. Fraser IS, Shearman RP, Smith A, Russell P. An association among blepharophimosis, resistant ovary syndrome, and true premature menopause. Fertil Steril. 1988;50(5):747–751. doi: 10.1016/s0015-0282(16)60309-6
  12. Nicolino M, Bost M, David M, Chaussain JL. Familial blepharophimosis: an uncommon marker of ovarian dysgenesis. J Pediatr Endocrinol Metab. 1995;8(2):127–133. doi: 10.1515/jpem.1995.8.2.127
  13. Uhlenhaut NH, Jakob S, Anlag K, et al. Somatic sex reprogramming of adult ovaries to testes by FOXL2 ablation. Cell. 2009;139(6):1130–1142. doi: 10.1016/j.cell.2009.11.021
  14. Méduri G, Bachelot A, Duflos C, et al. FOXL2 mutations lead to different ovarian phenotypes in BPES patients: Case Report. Hum Reprod. 2010;25(1):235–243. doi: 10.1093/humrep/dep355
  15. Caburet S, Arboleda VA, Llano E, et al. Mutant cohesin in premature ovarian failure. N Engl J Med. 2014;370(10):943–949. doi: 10.1056/NEJMoa1309635
  16. Xiao WJ, He WB, Zhang YX, et al. In-frame variants in STAG3 gene cause premature ovarian insufficiency. Front Genet. 2019;10:1016. doi: 10.3389/fgene.2019.01016
  17. Lacombe A, Lee H, Zahed L, et al. Disruption of POF1B binding to nonmuscle actin filaments is associated with premature ovarian failure. Am J Hum Genet. 2006;79(1):113–119. doi: 10.1086/505406
  18. Bolcun-Filas E, Hall E, Speed R, et al. Mutation of the mouse Syce1 gene disrupts synapsis and suggests a link between synaptonemal complex structural components and DNA repair. PLoS Genet. 2009;5(2):e1000393. Corrected and republished from: PLoS Genet. 2009;5(4). doi: 10.1371/journal.pgen.1000393
  19. de Vries L, Behar DM, Smirin-Yosef P, et al. Exome sequencing reveals SYCE1 mutation associated with autosomal recessive primary ovarian insufficiency. J Clin Endocrinol Metab. 2014;99(10):E2129–E2132. doi: 10.1210/jc.2014-1268
  20. de Vries FA, de Boer E, van den Bosch M, et al. Mouse Sycp1 functions in synaptonemal complex assembly, meiotic recombination, and XY body formation. Genes Dev. 2005;19(11):1376–1389. doi: 10.1101/gad.329705
  21. Bolcun-Filas E, Costa Y, Speed R, et al. SYCE2 is required for synaptonemal complex assembly, double strand break repair, and homologous recombination. J Cell Biol. 2007;176(6):741–747. doi: 10.1083/jcb.200610027
  22. Hamer G, Wang H, Bolcun-Filas E, et al. Progression of meiotic recombination requires structural maturation of the central element of the synaptonemal complex. J Cell Sci. 2008;121(Pt 15):2445–2451. doi: 10.1242/jcs.033233
  23. Wang J, Zhang W, Jiang H, Wu BL; Primary Ovarian Insufficiency Collaboration. Mutations in HFM1 in recessive primary ovarian insufficiency. N Engl J Med. 2014;370(10):972–974. doi: 10.1056/NEJMc1310150
  24. Zangen D, Kaufman Y, Zeligson S, et al. XX ovarian dysgenesis is caused by a PSMC3IP/HOP2 mutation that abolishes coactivation of estrogen-driven transcription. Am J Hum Genet. 2011;89(4):572–579. doi: 10.1016/j.ajhg.2011.09.006
  25. Weinberg-Shukron A, Renbaum P, Kalifa R, et al. A mutation in the nucleoporin-107 gene causes XX gonadal dysgenesis. J Clin Invest. 2015;125(11):4295–4304. doi: 10.1172/JCI83553
  26. Senger S, Csokmay J, Akbar T, et al. The nucleoporin Seh1 forms a complex with Mio and serves an essential tissue-specific function in Drosophila oogenesis. Development. 2011;138(10):2133–2142. Corrected and republished from: Development. 2011;138(12):2631. doi: 10.1242/dev.057372
  27. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995;268(5218):1749–1753. doi: 10.1126/science.7792600
  28. Barlow C, Hirotsune S, Paylor R, et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell. 1996;86(1):159–171. doi: 10.1016/s0092-8674(00)80086-0
  29. Liu H, Wei X, Sha Y, et al. Whole-exome sequencing in patients with premature ovarian insufficiency: early detection and early intervention. J Ovarian Res. 2020;13(1):114. doi: 10.1186/s13048-020-00716-6
  30. Lutzmann M, Grey C, Traver S, et al. MCM8- and MCM9-deficient mice reveal gametogenesis defects and genome instability due to impaired homologous recombination. Mol Cell. 2012;47(4):523–534. doi: 10.1016/j.molcel.2012.05.048
  31. AlAsiri S, Basit S, Wood-Trageser MA, et al. Exome sequencing reveals MCM8 mutation underlies ovarian failure and chromosomal instability. J Clin Invest. 2015;125(1):258–262. doi: 10.1172/JCI78473
  32. Wood-Trageser MA, Gurbuz F, Yatsenko SA, et al. MCM9 mutations are associated with ovarian failure, short stature, and chromosomal instability. Am J Hum Genet. 2014;95(6):754–762. doi: 10.1016/j.ajhg.2014.11.002
  33. Fauchereau F, Shalev S, Chervinsky E, et al. A non-sense MCM9 mutation in a familial case of primary ovarian insufficiency. Clin Genet. 2016;89(5):603–607. doi: 10.1111/cge.12736
  34. Goldberg Y, Halpern N, Hubert A, et al. Mutated MCM9 is associated with predisposition to hereditary mixed polyposis and colorectal cancer in addition to primary ovarian failure. Cancer Genet. 2015;208(12):621–624. doi: 10.1016/j.cancergen.2015.10.001
  35. Guo T, Zheng Y, Li G, et al. Novel pathogenic mutations in minichromosome maintenance complex component 9 (MCM9) responsible for premature ovarian insufficiency. Fertil Steril. 2020;113(4):845–852. doi: 10.1016/j.fertnstert.2019.11.015
  36. Qin Y, Guo T, Li G, et al. CSB-PGBD3 mutations cause premature ovarian failure. PLoS Genet. 2015;11(7):e1005419. doi: 10.1371/journal.pgen.1005419
  37. Santos MG, Machado AZ, Martins CN, et al. Homozygous inactivating mutation in NANOS3 in two sisters with primary ovarian insufficiency. Biomed Res Int. 2014;2014:787465. doi: 10.1155/2014/787465
  38. Wu X, Wang B, Dong Z, et al. A NANOS3 mutation linked to protein degradation causes premature ovarian insufficiency. Cell Death Dis. 2013;4(10):e825. doi: 10.1038/cddis.2013.368
  39. Mansouri MR, Schuster J, Badhai J, et al. Alterations in the expression, structure and function of progesterone receptor membrane component-1 (PGRMC1) in premature ovarian failure. Hum Mol Genet. 2008;17(23):3776–3783. doi: 10.1093/hmg/ddn274
  40. Ratts VS, Flaws JA, Kolp R, et al. Ablation of bcl-2 gene expression decreases the numbers of oocytes and primordial follicles established in the post-natal female mouse gonad. Endocrinology. 1995;136(8):3665–3668. doi: 10.1210/endo.136.8.7628407
  41. França MM, Mendonca BB. Genetics of primary ovarian insufficiency in the next-generation sequencing era. J Endocr Soc. 2019;4(2):bvz037. doi: 10.1210/jendso/bvz037
  42. Kasippillai T, MacArthur DG, Kirby A, et al. Mutations in eIF4ENIF1 are associated with primary ovarian insufficiency. J Clin Endocrinol Metab. 2013;98(9):E1534–E1539. doi: 10.1210/jc.2013-1102.
  43. Peng J, Li Q, Wigglesworth K, et al. Growth differentiation factor 9: bone morphogenetic protein 15 heterodimers are potent regulators of ovarian functions. Proc Natl Acad Sci USA. 2013;110(8):E776–E785. doi: 10.1073/pnas.1218020110
  44. Di Pasquale E, Beck-Peccoz P, Persani L. Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene. Am J Hum Genet. 2004;75(1):106–111. doi: 10.1086/422103
  45. Santos M, Cordts EB, Peluso C, et al. Association of BMP15 and GDF9 variants to premature ovarian insufficiency. J Assist Reprod Genet. 2019;36(10):2163–2169. doi: 10.1007/s10815-019-01548-0
  46. Dixit H, Rao LK, Padmalatha V, et al. Mutational screening of the coding region of growth differentiation factor 9 gene in Indian women with ovarian failure. Menopause. 2005;12(6):749–754. doi: 10.1097/01.gme.0000184424.96437.7a
  47. Laissue P, Christin-Maitre S, Touraine P, et al. Mutations and sequence variants in GDF9 and BMP15 in patients with premature ovarian failure. Eur J Endocrinol. 2006;154(5):739–744. doi: 10.1530/eje.1.02135
  48. Kovanci E, Rohozinski J, Simpson JL, et al. Growth differentiating factor-9 mutations may be associated with premature ovarian failure. Fertil Steril. 2007;87(1):143–146. doi: 10.1016/j.fertnstert.2006.05.079
  49. Qin Y, Choi Y, Zhao H, et al. NOBOX homeobox mutation causes premature ovarian failure. Am J Hum Genet. 2007;81(3):576–581. doi: 10.1086/519496
  50. Bouilly J, Bachelot A, Broutin I, et al. Novel NOBOX loss-of-function mutations account for 6.2% of cases in a large primary ovarian insufficiency cohort. Hum Mutat. 2011;32(10):1108–1113. doi: 10.1002/humu.21543
  51. Bayram Y, Gulsuner S, Guran T, et al. Homozygous loss-of-function mutations in SOHLH1 in patients with nonsyndromic hypergonadotropic hypogonadism. J Clin Endocrinol Metab. 2015;100(5):E808–E814. doi: 10.1210/jc.2015-1150
  52. Pangas SA, Choi Y, Ballow DJ, et al. Oogenesis requires germ cell-specific transcriptional regulators Sohlh1 and Lhx8. Proc Natl Acad Sci USA. 2006;103(21):8090–8095. doi: 10.1073/pnas.0601083103
  53. Aittomäki K, Lucena JL, Pakarinen P, et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell. 1995;82(6):959–968. doi: 10.1016/0092-8674(95)90275-9
  54. Vaskivuo TE, Aittomäki K, Anttonen M, et al. Effects of follicle-stimulating hormone (FSH) and human chorionic gonadotropin in individuals with an inactivating mutation of the FSH receptor. Fertil Steril. 2002;78(1):108–113. doi: 10.1016/s0015-0282(02)03148-5
  55. Meduri G, Touraine P, Beau I, et al. Delayed puberty and primary amenorrhea associated with a novel mutation of the human follicle-stimulating hormone receptor: clinical, histological, and molecular studies. J Clin Endocrinol Metab. 2003;88(8):3491–3498. doi: 10.1210/jc.2003-030217
  56. Huang W, Cao Y, Shi L. Effects of FSHR polymorphisms on premature ovarian insufficiency in human beings: a meta-analysis. Reprod Biol Endocrinol. 2019;17(1):80. doi: 10.1186/s12958-019-0528-1
  57. GeneCards. [Internet]. FIGLA gene (Protein Coding) folliculogenesis specific BHLH transcription factor. [cited 2021 Apr 25]. Available from: https://www.genecards.org/cgi-bin/carddisp.pl?gene=FIGLA
  58. Hu W, Gauthier L, Baibakov B, Jimenez-Movilla M, Dean J. FIGLA, a basic helix-loop-helix transcription factor, balances sexually dimorphic gene expression in postnatal oocytes. Mol Cell Biol. 2010;30(14):3661–3671. doi: 10.1128/MCB.00201-10
  59. Bayne RA, Martins da Silva SJ, Anderson RA. Increased expression of the FIGLA transcription factor is associated with primordial follicle formation in the human fetal ovary. Mol Hum Reprod. 2004;10(6):373–381. doi: 10.1093/molehr/gah056
  60. Tosh D, Rani HS, Murty US, et al. Mutational analysis of the FIGLA gene in women with idiopathic premature ovarian failure. Menopause. 2015;22(5):520–526. doi: 10.1097/GME.0000000000000340
  61. Pangas SA, Rajkovic A. Transcriptional regulation of early oogenesis: in search of masters. Hum Reprod Update. 2006;12(1):65–76. doi: 10.1093/humupd/dmi033
  62. Choi Y, Rajkovic A. Genetics of early mammalian folliculogenesis. Cell Mol Life Sci. 2006;63(5):579–590. doi: 10.1007/s00018-005-5394-7
  63. Chen B, Li L, Wang J, et al. Consanguineous familial study revealed biallelic FIGLA mutation associated with premature ovarian insufficiency. J Ovarian Res. 2018;11(1):48. doi: 10.1186/s13048-018-0413-0
  64. Legros F, Malka F, Frachon P, Lombès A, Rojo M. Organization and dynamics of human mitochondrial DNA. J Cell Sci. 2004;117(Pt 13):2653–2662. doi: 10.1242/jcs.01134
  65. Shoubridge EA, Wai T. Mitochondrial DNA and the mammalian oocyte. Curr Top Dev Biol. 2007;77:87–111. doi: 10.1016/S0070-2153(06)77004-1
  66. Bonomi M, Somigliana E, Cacciatore C, et al. Blood cell mitochondrial DNA content and premature ovarian aging. PLoS One. 2012;7(8):e42423. doi: 10.1371/journal.pone.0042423
  67. Pagnamenta AT, Taanman JW, Wilson CJ, et al. Dominant inheritance of premature ovarian failure associated with mutant mitochondrial DNA polymerase gamma. Hum Reprod. 2006;21(10):2467–2473. doi: 10.1093/humrep/del076
  68. Luoma P, Melberg A, Rinne JO, et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet. 2004;364(9437):875–882. doi: 10.1016/S0140-6736(04)16983-3
  69. Morino H, Pierce SB, Matsuda Y, et al. Mutations in Twinkle primase-helicase cause Perrault syndrome with neurologic features. Neurology. 2014;83(22):2054–2061. doi: 10.1212/WNL.0000000000001036
  70. Pierce SB, Walsh T, Chisholm KM, et al. Mutations in the DBP-deficiency protein HSD17B4 cause ovarian dysgenesis, hearing loss, and ataxia of Perrault syndrome. Am J Hum Genet. 2010;87(2):282–288. doi: 10.1016/j.ajhg.2010.07.007
  71. Matthijs G, Schollen E, Pardon E, et al. Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome). Nat Genet. 1997;16(1):88–92. Corrected and republished from: Nat Genet. 1997;16(3):316. doi: 10.1038/ng0597-88
  72. Peng T, Lv C, Tan H, et al. Novel PMM2 missense mutation in a Chinese family with non-syndromic premature ovarian insufficiency. J Assist Reprod Genet. 2020;37(2):443–450. doi: 10.1007/s10815-019-01675-8
  73. Silva CA, Yamakami LY, Aikawa NE, et al. Autoimmune primary ovarian insufficiency. Autoimmun Rev. 2014;13(4–5):427–430. doi: 10.1016/j.autrev.2014.01.003
  74. Cervato S, Mariniello B, Lazzarotto F, et al. Evaluation of the autoimmune regulator (AIRE) gene mutations in a cohort of Italian patients with autoimmune-polyendocrinopathy-candidiasis-ectodermal-dystrophy (APECED) and in their relatives. Clin Endocrinol (Oxf). 2009;70(3):421–428. doi: 10.1111/j.1365-2265.2008.03318.x
  75. MedlinePlus. [Internet]. AIRE gene autoimmune regulator. [cited 2021 Apr 25]. Available from: https://medlineplus.gov/genetics/gene/aire/
  76. Kahaly GJ. Polyglandular autoimmune syndromes. Eur J Endocrinol. 2009;161(1):11–20. doi: 10.1530/EJE-09-0044
  77. Santoro MR, Bray SM, Warren ST. Molecular mechanisms of fragile X syndrome: a twenty-year perspective. Annu Rev Pathol. 2012;7:219–245. doi: 10.1146/annurev-pathol-011811-132457
  78. Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D, et al. Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study--preliminary data. Am J Med Genet. 1999;83(4):322–325.
  79. Chen E, Joseph S. Fragile X mental retardation protein: A paradigm for translational control by RNA-binding proteins. Biochimie. 2015;114:147–154. doi: 10.1016/j.biochi.2015.02.005
  80. Primerano B, Tassone F, Hagerman RJ, et al. Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations. RNA. 2002;8(12):1482–1488.
  81. Winship AL, Stringer JM, Liew SH, Hutt KJ. The importance of DNA repair for maintaining oocyte quality in response to anti-cancer treatments, environmental toxins and maternal ageing. Hum Reprod Update. 2018;24(2):119–134. doi: 10.1093/humupd/dmy002
  82. Stringer JM, Winship A, Liew SH, Hutt K. The capacity of oocytes for DNA repair. Cell Mol Life Sci. 2018;75(15):2777–2792. doi: 10.1007/s00018-018-2833-9
  83. Oktay K, Turan V, Titus S, et al. BRCA mutations, DNA repair deficiency, and ovarian aging. Biol Reprod. 2015;93(3):67. doi: 10.1095/biolreprod.115.132290
  84. Titus S, Li F, Stobezki R, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013;5(172):172ra21. doi: 10.1126/scitranslmed.3004925
  85. Ben-Aharon I, Levi M, Margel D, et al. Premature ovarian aging in BRCA carriers: a prototype of systemic precocious aging? Oncotarget. 2018;9(22):15931–15941. doi: 10.18632/oncotarget.24638
  86. Rzepka-Górska I, Tarnowski B, Chudecka-Głaz A, et al. Premature menopause in patients with BRCA1 gene mutation. Breast Cancer Res Treat. 2006;100(1):59–63. doi: 10.1007/s10549-006-9220-1
  87. Finch A, Valentini A, Greenblatt E, et al. Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril. 2013;99(6):1724–1728. doi: 10.1016/j.fertnstert.2013.01.109
  88. Lin WT, Beattie M, Chen LM, et al. Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer. 2013;119(9):1652–1659. doi: 10.1002/cncr.27952
  89. Izhar R, Husain S, Tahir S, Husain S. Occult form of premature ovarian insufficiency in women with infertility and oligomenorrhea as assessed by poor ovarian response criteria. J Reprod Infertil. 2017;18(4):361–367.
  90. Esteves SC, Alviggi C, Humaidan P, et al. The POSEIDON criteria and its measure of success through the eyes of clinicians and embryologists. Front Endocrinol (Lausanne). 2019;10:814. doi: 10.3389/fendo.2019.00814
  91. Humaidan P, La Marca A, Alviggi C, et al. Future perspectives of POSEIDON stratification for clinical practice and research. Front Endocrinol (Lausanne). 2019;10:439. doi: 10.3389/fendo.2019.00439
  92. Polyzos NP, Drakopoulos P. Management strategies for POSEIDON›s group 1. Front Endocrinol (Lausanne). 2019;10:679. doi: 10.3389/fendo.2019.00679
  93. Sunkara SK, Ramaraju GA, Kamath MS. Management strategies for POSEIDON group 2. Front Endocrinol (Lausanne). 2020;11:105. doi: 10.3389/fendo.2020.00105
  94. Haahr T, Dosouto C, Alviggi C, et al. Management strategies for POSEIDON groups 3 and 4. Front Endocrinol (Lausanne). 2019;10:614. doi: 10.3389/fendo.2019.00614

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Eсо-Vector



Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».